N

ew drugs are moving more quickly to market today compared with those launched during the height of the Great Recession, but the pipeline is no faster than it was two decades ago.

That’s a key finding of a new report, released jointly by QuintilesIMS Institute and STAT, that illustrates shifting forces that have high stakes for drug innovation and pricing. The report, which analyzed the lifespans of 667 new drugs launched in the United States over the past two decades, was prepared independently by the QuintilesIMS Institute, in consultation with STAT.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Not sure if this is an issue with my device, but the link to the .pdf of the report does not work and redirects to InstaPage’s error page.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.